Sign In
Buy OCUP
$1.17
+0 (+0%)
At Close: Jan 22, 2025
The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics
12:00pm, Friday, 25'th Oct 2024
The resulting company will operate under the name Opus Genetics and the Nasdaq ticker symbol (IRD) RALEIGH, N.C. , Oct. 25, 2024 /PRNewswire/ -- The RD Fund (Retinal Degeneration Fund) – the ventu
Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal
03:25pm, Wednesday, 23'rd Oct 2024
On Wednesday, Ocuphire Pharma, Inc. OCUP announced the all-stock acquisition of Opus Genetics, Inc., a clinical-stage gene therapy company for inherited retinal diseases (IRDs).
Shareholder Alert: Ademi LLP Investigates Whether Ocuphire Pharma, Inc. Is Breaching Its Duties to Its Public Shareholders
09:05am, Wednesday, 23'rd Oct 2024
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Ocuphire (Nasdaq: OCUP) for possible breaches of fiduciary duty and other violations of law in its transaction with Opus Genetics. Click here to
Ocuphire Pharma Announces Acquisition of Opus Genetics
04:05pm, Tuesday, 22'nd Oct 2024
Acquisition creates a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations
Published data from two Phase 3 clinical trials demonstrated rapid reversal of pharmacologically-induced mydriasis with favorable safety profile Published data from two Phase 3 clinical trials demonst
UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia
08:43pm, Thursday, 05'th Sep 2024
Top-line data from VEGA-3 Phase 3 trial expected in first half of 2025 Top-line data from LYNX-2 Phase 3 trial in patients with decreased visual acuity under low light conditions following keratorefra
Ocuphire Pharma, Inc. (OCUP) Reports Q2 Loss, Lags Revenue Estimates
10:10am, Tuesday, 13'th Aug 2024
Ocuphire Pharma, Inc. (OCUP) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.24 per share a year ago.
Ocuphire Pharma to Present at Two Investor Conferences in August
08:00am, Thursday, 08'th Aug 2024
FARMINGTON HILLS, Mich., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-m
Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July
08:00am, Wednesday, 10'th Jul 2024
CEO to participate in ARVO SIG panel on oral medications for retinal diseases ZETA-1 Phase 2 clinical trial subset analysis to be presented during the ASRS 42 nd Annual Scientific Meeting FARMINGTON H
Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June
07:57am, Thursday, 06'th Jun 2024
FARMINGTON HILLS, Mich., June 06, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing small molecule therap
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
08:00am, Friday, 10'th May 2024
FARMINGTON HILLS, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing small molecule therapies for
Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting
08:00am, Monday, 06'th May 2024
FARMINGTON HILLS, Mich., May 06, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing novel therapies for th
Ocuphire Pharma to Present at the Aegis Virtual Conference
08:00am, Friday, 03'rd May 2024
FARMINGTON HILLS, Mich., May 03, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of re
Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
08:00am, Monday, 22'nd Apr 2024
FARMINGTON HILLS, Mich., April 22, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing novel therapies for
LYNX-2 Follows SPA Agreement with FDA Development of PS is Funded by Ocuphire's Partner Viatris FARMINGTON HILLS, Mich., April 11, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clin
